Liraglutide Research Overview: The Original Long-Acting GLP-1 Agonist
Liraglutide was the first long-acting glucagon-like peptide-1 (GLP-1) receptor agonist to be characterized at the molecular level, and remains the prototype research compound for studying acylation-mediated half-life extension of native incretin peptides. While the more recent semaglutide and tirzepatide compounds have captured a larger share of current research attention, liraglutide retains a specific research niche: it sits in a shorter half-life window than semaglutide, making it useful for research designs that require modestly extended GLP-1R engagement without the week-long exposure profile of newer analogs.
Liraglutide is supplied for in vitro and animal-research applications only.
Reference identifiers
- CAS Registry Number: 204656-20-2
- Molecular formula: C₁₇₂H₂₆₅N₄₃O₅₁
- Molecular weight: ~3751 g/mol
- Sequence length: 31 amino acids (modified GLP-1(7-37) backbone)
- Modification: C16 palmitic acid via γ-glutamic acid spacer at Lys-26
- Form supplied: Lyophilized white powder
The CoA should report HPLC purity ≥99.0% with chromatogram visible, mass spec confirmation within ±0.5 Da of theoretical, net peptide content, and the C16 fatty-acid modification confirmed by mass shift. Any reputable research-supply vendor should publish the CoA per lot; verify that the lot number on the vial resolves to a downloadable PDF before use.
Structure and design
Liraglutide is built on the native human GLP-1(7-37) backbone, with two key modifications relative to the parent peptide:
- Lys-34 → Arg substitution — preserves the C16 attachment site selectivity (eliminates the alternative lysine that would otherwise compete for acylation).
- C16 palmitic acid attached via γ-glutamic acid spacer at Lys-26 — provides the albumin-binding moiety that extends circulating half-life.
The substitution at position 34 is a synthesis-engineering choice that ensures the C16 attachment goes to the intended Lys-26 site. Without it, the peptide would have two competing acylation sites and the synthesis would produce a mixture of regioisomers.
The C16 palmitic acid is shorter than the C18 di-acid used in semaglutide. This shorter fatty acid produces weaker but still substantial albumin binding, giving liraglutide a circulating half-life of approximately 13 hours in animal models — versus approximately one week for semaglutide.
Mechanism
Liraglutide binds the GLP-1 receptor (GLP-1R) with high affinity, mimicking the action of endogenous GLP-1. Downstream signaling follows the canonical GLP-1R pathway:
- Activation of Gαs and increased intracellular cAMP
- PKA and EPAC2 signaling cascade engagement
- Glucose-dependent insulin secretion from pancreatic β-cells
- α-cell glucagon suppression
- Delayed gastric emptying via vagal afferent and direct smooth-muscle effects
- Central satiety signaling via hypothalamic and brainstem GLP-1R neurons
The mechanism is functionally identical to that of semaglutide — both are GLP-1R monoagonists. The difference is duration of receptor engagement.
Why liraglutide rather than semaglutide?
For most modern research designs, semaglutide is the GLP-1R monoagonist of choice owing to its longer half-life and consequently more stable steady-state exposure profile in animal studies. Liraglutide retains specific research utility:
- Shorter-window receptor engagement — research designs probing GLP-1R activation over a daily cycle, rather than a weekly cycle, may benefit from liraglutide’s shorter half-life
- Acylation-mediated half-life extension as the variable of interest — for research investigating fatty-acid length and albumin-binding mechanism specifically, liraglutide (C16) and semaglutide (C18 di-acid) form a useful comparator pair
- Legacy literature compatibility — a large preclinical literature exists for liraglutide; research designs aiming for direct comparison with that literature may select liraglutide for that reason alone
- Faster onset, faster clearance — for research designs requiring acute-phase characterization without prolonged steady-state effects
Preclinical animal-study findings
The published liraglutide preclinical literature is extensive — among the largest of any GLP-1 research compound. Reported findings in animal-study models include:
- Reduced food intake in DIO mouse and rat models
- Improved glucose tolerance in animal models of type 2 diabetes
- β-cell preservation and improved insulin secretion dynamics
- Cardiovascular markers modulated in cardiometabolic disease models
- Modulation of inflammatory markers in animal models of metabolic dysfunction
- Effects on hepatic lipid content in fatty liver models, though smaller than reported for dual- and triple-agonist compounds
The depth of the liraglutide preclinical literature makes it a useful reference compound — research designs investigating novel GLP-1R agonists frequently include liraglutide as a comparator.
For broader context on where liraglutide sits in the current incretin research catalog, see the GLP-1 research landscape Q2 2026.
CoA verification
A research-grade liraglutide CoA should document:
– HPLC purity ≥99.0% with chromatogram visible
– Mass spectrum confirming expected ~3751 Da [M+H]⁺ within ±0.5 Da
– Acylation confirmation — the C16 palmitic acid modification at Lys-26 confirmed by mass shift relative to unmodified backbone, or by tandem MS
– Sequence confirmation including the Lys-34 → Arg substitution
– Net peptide content with counterion identified
– Lot number matching the vial
The acylation check is essential. Without the C16 fatty-acid modification, the underlying peptide is essentially native GLP-1(7-37) with a single substitution — a fundamentally different research tool.
Storage
Liraglutide is supplied lyophilized. Pre-reconstitution: 2–8°C, dry, away from light; -20°C for archival storage. Post-reconstitution: 2–8°C in multi-dose diluent, use within ~28 days. Reconstitute by adding diluent slowly to vial wall; gentle inversion only.
Comparison with semaglutide at a glance
| Feature | Liraglutide | Semaglutide |
|---|---|---|
| Sequence length | 31 aa | 31 aa |
| Backbone substitutions | Lys-34 → Arg | Aib-2, Lys-34 → Arg |
| Fatty acid | C16 palmitic | C18 diacid |
| Spacer | γGlu | γGlu-2xOEG |
| Half-life (animal models) | ~13 hours | ~1 week |
| GLP-1R signaling profile | Canonical | Canonical |
Summary
Liraglutide is the original long-acting GLP-1 receptor monoagonist, built on the GLP-1(7-37) backbone with C16 palmitic acid albumin-binding modification. It produces canonical GLP-1R signaling with a circulating half-life intermediate between native GLP-1 (minutes) and semaglutide (~1 week). Its extensive preclinical literature and shorter exposure window relative to semaglutide make it useful as a comparator compound for research designs investigating GLP-1R biology, acylation-mediated half-life extension, or shorter-window receptor engagement profiles.
Research Use Only. Not for use in or on humans or animals. Not a food, drug, cosmetic, or supplement.